Home » Newsletters » BioWorld Science

BioWorld Science

June 9, 2008

View Archived Issues

GDC-0449 shows safety and good PK profile in patients with advanced solid cancers

CuraGen reports results from phase I/II study of CR011-vcMMAE

Preclinical evaluation of novel gene therapy for the treatment of hereditary inclusion-body myositis

JNK inhibition shows benefit in experimental endometriosis

Novartis presents update on pipeline of novel vaccine candidates

First phase I clinical results for JM-1232 reported

TorreyPines initiates phase I clinical trial for oral prodrug of tezampanel

Positive opinion issued to broaden use of Erbitux, including first-line colorectal cancer

Indevus presents update on NDA for Nebido

Achillion nominates ACH-1625 as first clinical candidate in HCV protease program

Nuvelo initiates enrollment in phase Ib trial of bolus plus infusion dosing of NU-172

Nine European countries grant national marketing authorizations to SpePharm's Loramyc

Transcept to submit NDA to FDA for Intermezzo in the third quarter of 2008

Medicago reports positive results from preclinical study in ferrets of H5N1 VLP vaccine

Ipsen to acquire Tercica

FDA approves Angioblast's IND application to initiate phase II trial of allogeneic stem cells

Intercytex completes enrollment in phase III trial of Cyzact in venous leg ulcers

Arana successfully engineers second candidate antibody under collaboration with CSL

Merck Serono and ZymoGenetics initiate phase II/III trial of atacicept in SLE

Epix identifies three lead candidates in third G-protein-coupled receptor discovery program

CHMP recommends refusing Takeda's MAA for ramelteon

PharmaGap's PhG-alpha-1 reduces tumor size, increases survival in colon cancer models

Recent Devgen patent discloses novel agents for glaucoma

Novel antiinflammatory agents disclosed in recent patent literature

Recent Roche patent reports new therapeutic agents for urological disorders

Popular Stories

News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...